BAJAJ BROKING

Notification
No new Notification messages
Dr Agarwal's Health Care IPO is Open!
Apply for the Dr Agarwal's Health Care IPO through UPI in just minutes.
Q3 FY'25 Results of Top Companies!
From Reliance Industries to TCS to HDFC Bank, check out the latest quarterly results with financial highlights, key performance metrics, and more!
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Cipla Q3 Results FY24-25: Revenue increases by 469.16 Crore YoY, Net Profit Increases by 506.08 Crore YoY

Cipla, a leading pharmaceutical company, has announced its financial results for the third quarter of the fiscal year 2024-2025, ending December 31, 2024. The company reported a consolidated net profit of ₹1,574.59 crore, a significant increase from ₹1,068.51 crore in the same quarter of the previous year. This robust performance is attributed to strong demand, particularly in the North American market.

CIPLA LTD

Trade

1457.4533.50 (2.35 %)

Updated - 30 January 2025
1469.80day high
DAY HIGH
1426.00day low
DAY LOW
1773294
VOLUME (BSE)

Key Highlights/Quick Insights of Cipla Q3 Results

  • Revenue Growth: Total revenue from operations reached ₹7,072.97 crore, up from ₹6,603.81 crore in Q3 FY23.

  • Profit Before Tax: The company reported a profit before tax of ₹1,916.09 crore, compared to ₹1,473.81 crore in the same quarter last year.

  • Net Profit: Net profit after tax stood at ₹1,574.59 crore, a substantial increase from ₹1,068.41 crore in Q3 FY23.

Quarterly Cipla Q3 Results FY24-25  

In the third quarter, Cipla's revenue from the sale of products was ₹6,961.60 crore, up from ₹6,505.66 crore in the same period last year. Other operating revenue also saw an increase, contributing to the overall growth in total revenue from operations.

Segment Highlights

Pharmaceuticals: Strong Revenue & Profit Growth

  • Revenue grew 6.5% YoY to ₹6,777.84 crore, up from ₹6,365.06 crore.

  • Quarterly profit rose to ₹1,888.86 crore, a 10.7% YoY increase from ₹1,780.73 crore.

  • 9M FY25 revenue stood at ₹19,942.70 crore, reflecting steady growth from ₹18,846.08 crore in 9M FY24.

New Ventures: Turnaround in Profitability

  • Revenue climbed to ₹341.30 crore, up 21.7% YoY from ₹280.51 crore.

  • Segment profit stood at ₹41.87 crore, reversing a loss of ₹6.86 crore in Q3 FY24.

  • 9M FY25 revenue grew 12.9% YoY to ₹1,014.88 crore, up from ₹898.73 crore.

Overall Performance

  • Total segment revenue increased 7.1% YoY to ₹7,119.14 crore from ₹6,645.57 crore.

  • Total segment profit rose 13.6% YoY to ₹1,930.73 crore, driven by strong pharma growth.

  • Exceptional item impact of ₹194.82 crore in new ventures affected the bottom line.

  • Profit before tax improved 30% YoY to ₹1,916.09 crore from ₹1,473.81 crore.

Also read: Dr Reddy's Q3 Results FY24-25 Highlights, Revenue Up 16% YoY, Net Profit at ₹1,413.3 Crore (Consolidated)

Sector expectations for Cipla Q3 Results FY24-25 

Cipla's performance has surpassed market expectations, with a nearly 49% increase in consolidated net profit, reaching ₹1,574.59 crore for the October-December quarter. This figure exceeded analysts' estimates between ₹1,170 crore and ₹1,217 crore, highlighting the company's strong market position and effective strategy execution.

Management Commentary

Umang Vohra MD and Global CEO of Cipla quoted that “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position.

Financial Table – With All Major Metrices and Numbers (Consolidated)

Particulars

31-12-2024

31-12-2023

Revenue from sale of products

6,961.60

6,505.66

Other operating revenue

111.37

98.15

Total revenue from operations

7,072.97

6,603.81

Other income

221.61

184.63

Total income

7,294.58

6,788.44

Cost of materials consumed

1,296.73

1,196.18

Purchases of stock-in-trade

913.23

927.21

Changes in inventories

54.12

96.14

Employee benefits expense

1,197.62

1,068.13

Finance costs

14.64

30.10

Depreciation and amortisation expense

279.80

233.43

Other expenses

1,622.35

1,568.62

Total expenses

5,378.49

5,119.81

Profit before tax

1,916.09

1,473.81

Tax expense

332.37

405.30

Net profit after tax

1,583.72

1,068.51

Share of profit/loss of associates

(9.13)

(0.10)

Net profit for the period

1,574.59

1,068.51

Note: All financial figures are sourced from Cipla’s official quarterly earnings report.

The financial data for Cipla Q3 FY24-25 results is sourced from BSE.

Cipla Q3 Results FY24-25: Projected ₹3.1-7% YoY Revenue Increase

Cipla is set to announce its Q3 FY24-25 financial results on January 28, 2025. Analysts anticipate a revenue increase of 3.1% to 7% year-over-year, with figures projected between ₹6,807 crore and ₹7,070 crore. However, margins are expected to decline both annually and sequentially.

Key Highlights:

  • Revenue Growth: Projected increase of 3.1% to 7% YoY, reaching ₹6,807–7,070 crore.

  • Profit After Tax (PAT): Estimates range from a 2.2% decrease to a 14% increase YoY, with figures between ₹1,170 crore and ₹1,217 crore.

  • Margin Outlook: Expected decline in margins on both YoY and sequential bases.

  • Key Focus Areas: Updates on drugs like Abraxane and Lanreotide, along with timelines for upcoming launches.

Quarterly Performance Overview:

Analysts project Cipla's Q3 FY24-25 revenue to be in the range of ₹6,807 crore to ₹7,070 crore, reflecting a YoY growth of 3.1% to 7%. Profit after tax is estimated between ₹1,170 crore and ₹1,217 crore, indicating a potential decrease of 2.2% or an increase of up to 14% compared to the same quarter last year. Margins are anticipated to face pressure both annually and sequentially.

Note: These figures are based on analyst estimates and are subject to change upon the official release of Cipla's financial results.

The financial data estimates for Cipla Q3 FY24-25 results are sourced from Economic Times.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5300+ Cr MTF Book

icon-with-text